TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB | Market Closed - Börse Stuttgart 02:18:14 2024-06-21 am EDT | ||
| 20.53 EUR | -1.58% |
|
| Current month | +7.66% | ||
| 1 month | +17.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 20.53 | -1.58% |
| 24-06-20 | 20.86 | -1.51% |
| 24-06-19 | 21.18 | +3.32% |
| 24-06-18 | 20.5 | +0.89% |
| 24-06-17 | 20.32 | +0.15% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 02:18 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SD9S0J |
| ISIN | DE000SD9S0J2 |
| Date issued | 2021-01-18 |
| Strike | 3,330 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 12.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.57 € |
|---|---|
| Lowest since issue | 2.07 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,806
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.43%
- Stock Market
- Certificates
- Certificat
